Design, Stability and Efficacy of a New Targeting Peptide for Nanoparticulate Drug Delivery to SH-SY5Y Neuroblastoma Cells

Rachel Huey, Dan Rathbone, P. A. McCarron, Susan Hawthorne

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

In recent years, rabies virus-derived peptide (RDP) has shown promise as a specific neural cell targeting ligand, however stability of the peptide in human serum was unknown. Herein, we report the molecular modelling and design of an optimised peptide sequence based on interactions of RDP with the 7 subunit of the nicotinic acetylcholine receptor (nAChR). The new sequence, named DAS, designed around a 5-mer sequence which demonstrated optimal nAChR binding in silico, showed greatly improved stability for up to 8 hours in human serum in comparison to RDP, which degraded within 2 hours at 37 °C. In vitro analysis using SH-SY5Y neuroblastoma cells showed that DAS-conjugated nanoparticles containing the cytotoxic drug doxorubicin (DAS-Dox-NP) displayed significantly enhanced cytotoxicity compared with untargeted doxorubicin-loaded nanoparticles (Dox-NP). DAS-Dox-NP had no significant effect on non-neural cell types, confirming its neural-specific targeting properties.
In this manuscript, we report the design and testing of an optimised peptide ligand, conjugated to a nanoparticulate delivery vehicle and specifically targeted to neural cells.. Future impact of an innovative targeting peptide ligand combining the ability to selectively identify the target and facilitate cellular internalisation could enable the successful treatment of many neural cell disorders.
LanguageEnglish
Pages959-970
Number of pages12
JournalJournal of Drug Targeting
Volume27
Issue number9
Early online date9 Jan 2019
DOIs
Publication statusPublished - 31 Jan 2019

Fingerprint

amsonic acid
Neuroblastoma
Peptides
Rabies virus
Nanoparticles
Doxorubicin
Pharmaceutical Preparations
Nicotinic Receptors
Ligands
Serum
Computer Simulation

Keywords

  • Peptide targeting
  • RDP
  • drug delivery
  • nanoparticle
  • neural cell

Cite this

@article{137e09c50572450d826ca452168cf606,
title = "Design, Stability and Efficacy of a New Targeting Peptide for Nanoparticulate Drug Delivery to SH-SY5Y Neuroblastoma Cells",
abstract = "In recent years, rabies virus-derived peptide (RDP) has shown promise as a specific neural cell targeting ligand, however stability of the peptide in human serum was unknown. Herein, we report the molecular modelling and design of an optimised peptide sequence based on interactions of RDP with the 7 subunit of the nicotinic acetylcholine receptor (nAChR). The new sequence, named DAS, designed around a 5-mer sequence which demonstrated optimal nAChR binding in silico, showed greatly improved stability for up to 8 hours in human serum in comparison to RDP, which degraded within 2 hours at 37 °C. In vitro analysis using SH-SY5Y neuroblastoma cells showed that DAS-conjugated nanoparticles containing the cytotoxic drug doxorubicin (DAS-Dox-NP) displayed significantly enhanced cytotoxicity compared with untargeted doxorubicin-loaded nanoparticles (Dox-NP). DAS-Dox-NP had no significant effect on non-neural cell types, confirming its neural-specific targeting properties. In this manuscript, we report the design and testing of an optimised peptide ligand, conjugated to a nanoparticulate delivery vehicle and specifically targeted to neural cells.. Future impact of an innovative targeting peptide ligand combining the ability to selectively identify the target and facilitate cellular internalisation could enable the successful treatment of many neural cell disorders.",
keywords = "Peptide targeting, RDP, drug delivery, nanoparticle, neural cell",
author = "Rachel Huey and Dan Rathbone and McCarron, {P. A.} and Susan Hawthorne",
year = "2019",
month = "1",
day = "31",
doi = "10.1080/1061186X.2019.1567737",
language = "English",
volume = "27",
pages = "959--970",
journal = "Journal of Drug Targeting",
issn = "1029-2330",
number = "9",

}

Design, Stability and Efficacy of a New Targeting Peptide for Nanoparticulate Drug Delivery to SH-SY5Y Neuroblastoma Cells. / Huey, Rachel; Rathbone, Dan; McCarron, P. A.; Hawthorne, Susan.

In: Journal of Drug Targeting, Vol. 27, No. 9, 31.01.2019, p. 959-970.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Design, Stability and Efficacy of a New Targeting Peptide for Nanoparticulate Drug Delivery to SH-SY5Y Neuroblastoma Cells

AU - Huey, Rachel

AU - Rathbone, Dan

AU - McCarron, P. A.

AU - Hawthorne, Susan

PY - 2019/1/31

Y1 - 2019/1/31

N2 - In recent years, rabies virus-derived peptide (RDP) has shown promise as a specific neural cell targeting ligand, however stability of the peptide in human serum was unknown. Herein, we report the molecular modelling and design of an optimised peptide sequence based on interactions of RDP with the 7 subunit of the nicotinic acetylcholine receptor (nAChR). The new sequence, named DAS, designed around a 5-mer sequence which demonstrated optimal nAChR binding in silico, showed greatly improved stability for up to 8 hours in human serum in comparison to RDP, which degraded within 2 hours at 37 °C. In vitro analysis using SH-SY5Y neuroblastoma cells showed that DAS-conjugated nanoparticles containing the cytotoxic drug doxorubicin (DAS-Dox-NP) displayed significantly enhanced cytotoxicity compared with untargeted doxorubicin-loaded nanoparticles (Dox-NP). DAS-Dox-NP had no significant effect on non-neural cell types, confirming its neural-specific targeting properties. In this manuscript, we report the design and testing of an optimised peptide ligand, conjugated to a nanoparticulate delivery vehicle and specifically targeted to neural cells.. Future impact of an innovative targeting peptide ligand combining the ability to selectively identify the target and facilitate cellular internalisation could enable the successful treatment of many neural cell disorders.

AB - In recent years, rabies virus-derived peptide (RDP) has shown promise as a specific neural cell targeting ligand, however stability of the peptide in human serum was unknown. Herein, we report the molecular modelling and design of an optimised peptide sequence based on interactions of RDP with the 7 subunit of the nicotinic acetylcholine receptor (nAChR). The new sequence, named DAS, designed around a 5-mer sequence which demonstrated optimal nAChR binding in silico, showed greatly improved stability for up to 8 hours in human serum in comparison to RDP, which degraded within 2 hours at 37 °C. In vitro analysis using SH-SY5Y neuroblastoma cells showed that DAS-conjugated nanoparticles containing the cytotoxic drug doxorubicin (DAS-Dox-NP) displayed significantly enhanced cytotoxicity compared with untargeted doxorubicin-loaded nanoparticles (Dox-NP). DAS-Dox-NP had no significant effect on non-neural cell types, confirming its neural-specific targeting properties. In this manuscript, we report the design and testing of an optimised peptide ligand, conjugated to a nanoparticulate delivery vehicle and specifically targeted to neural cells.. Future impact of an innovative targeting peptide ligand combining the ability to selectively identify the target and facilitate cellular internalisation could enable the successful treatment of many neural cell disorders.

KW - Peptide targeting

KW - RDP

KW - drug delivery

KW - nanoparticle

KW - neural cell

UR - http://www.scopus.com/inward/record.url?scp=85060930926&partnerID=8YFLogxK

UR - https://pure.ulster.ac.uk/en/publications/design-stability-and-efficacy-of-a-new-targeting-peptide-for-nano

U2 - 10.1080/1061186X.2019.1567737

DO - 10.1080/1061186X.2019.1567737

M3 - Article

VL - 27

SP - 959

EP - 970

JO - Journal of Drug Targeting

T2 - Journal of Drug Targeting

JF - Journal of Drug Targeting

SN - 1029-2330

IS - 9

ER -